We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
Stockal+Disclaimer.pdf
3 own
2 watching
Current Price
$9.26
$0.02
(0.22%)
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
1,611.92M
52-Week High
21.1894
52-Week Low
4.92
Average Volume
0.35M
Dividend Yield
--
P/E Ratio
--
Market Capitalization1,611.92M
52-Week High21.1894
52-Week Low4.92
Average Volume0.35M
Dividend Yield--
P/E Ratio--
What does the Stockal+Disclaimer.pdf do?
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis. Its preclinical stage product includes REC-3964 to treat Clostridium difficile colitis; REC-64917 for the treat of neural or systemic inflammation; REC-65029 to treat HRD-negative ovarian cancer; REC-648918 to enhance anti-tumor immune; REC-2029 for the treatment of wnt-mutant hepatocellular carcinoma; REC-14221 to treat solid and hematological malignancies; and REC-64151 for the treatment of immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Read More
How much money does Stockal+Disclaimer.pdf make?
News & Events about Stockal+Disclaimer.pdf.
Zolmax
2 months ago
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX Get Rating) insider Shafique Virani sold 10,000 shares of the businesss stock in a transaction that occurred on Thursday, September 15th. The shares were sold at an average price of $13.36, for a total value of $133,600.00. Following the ...
Zolmax
3 months ago
Exscientia (NASDAQ:EXAI Get Rating) and Recursion Pharmaceuticals (NASDAQ:RXRX Get Rating) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, institutional ...
PR Newswire
5 months ago
Recursion Announces Initiation of Phase 2/3 Trial for the Treatment of NF2-Mutated Meningiomas at Children's Tumor Foundation NF Conference Recursion Announces Initiation of Phase 2/3 Trial for the Treatment of NF2-Mutated Meningiomas at Children's Tumor Foundation NF Conference PR Newswire SALT...
Zolmax
5 months ago
Bank of America Corp DE grew its position in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX Get Rating) by 545.8% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 171,175 shares of the companys stock after acquiring...
PR Newswire
5 months ago
Recursion to Participate in Upcoming Investor Conferences Recursion to Participate in Upcoming Investor Conferences PR Newswire SALT LAKE CITY, June 2, 2022 SALT LAKE CITY, June 2, 2022 /PRNewswire/ --Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery...
Frequently Asked Questions
Frequently Asked Questions
What is Stockal+Disclaimer.pdf share price today?
plus_minus_icon
Can Indians buy Stockal+Disclaimer.pdf shares?
plus_minus_icon
How can I buy Stockal+Disclaimer.pdf shares from India?
plus_minus_icon
Can Fractional shares of Stockal+Disclaimer.pdf be purchased?
plus_minus_icon
What are the documents required to start investing in Stockal+Disclaimer.pdf stocks?
plus_minus_icon
What is today’s traded volume of Stockal+Disclaimer.pdf?
plus_minus_icon
What is today’s market capitalisation of Stockal+Disclaimer.pdf?
plus_minus_icon
What is the 52-Week High and Low Range of Stockal+Disclaimer.pdf?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf down from its 52-Week High?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf up from its 52-Week Low?
plus_minus_icon
Current Price
$9.26
$0.02
(0.22%)
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00